# Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

> **NCT02581345** · PHASE3 · COMPLETED · sponsor: **Momenta Pharmaceuticals, Inc.** · enrollment: 572 (actual)

## Conditions studied

- Chronic Plaque Psoriasis
- Psoriasis

## Interventions

- **BIOLOGICAL:** M923
- **BIOLOGICAL:** Humira

## Key facts

- **NCT ID:** NCT02581345
- **Lead sponsor:** Momenta Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-04-04
- **Final completion:** 2017-04-04
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581345, "Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02581345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*